Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Pulmonary Department, Pinehurst Medical Clinic and FirstHealth Moore Regional Hospital, Pinehurst, North Carolina.
J Thorac Oncol. 2019 Mar;14(3):445-458. doi: 10.1016/j.jtho.2018.11.013. Epub 2018 Nov 23.
Electromagnetic navigation bronchoscopy (ENB) is a minimally invasive technology that guides endoscopic tools to pulmonary lesions. ENB has been evaluated primarily in small, single-center studies; thus, the diagnostic yield in a generalizable setting is unknown.
NAVIGATE is a prospective, multicenter, cohort study that evaluated ENB using the superDimension navigation system (Medtronic, Minneapolis, Minnesota). In this United States cohort analysis, 1215 consecutive subjects were enrolled at 29 academic and community sites from April 2015 to August 2016.
The median lesion size was 20.0 mm. Fluoroscopy was used in 91% of cases (lesions visible in 60%) and radial endobronchial ultrasound in 57%. The median ENB planning time was 5 minutes; the ENB-specific procedure time was 25 minutes. Among 1157 subjects undergoing ENB-guided biopsy, 94% (1092 of 1157) had navigation completed and tissue obtained. Follow-up was completed in 99% of subjects at 1 month and 80% at 12 months. The 12-month diagnostic yield was 73%. Pathology results of the ENB-aided tissue samples showed malignancy in 44% (484 of 1092). Sensitivity, specificity, positive predictive value, and negative predictive value for malignancy were 69%, 100%, 100%, and 56%, respectively. ENB-related Common Terminology Criteria for Adverse Events grade 2 or higher pneumothoraces (requiring admission or chest tube placement) occurred in 2.9%. The ENB-related Common Terminology Criteria for Adverse Events grade 2 or higher bronchopulmonary hemorrhage and grade 4 or higher respiratory failure rates were 1.5% and 0.7%, respectively.
NAVIGATE shows that an ENB-aided diagnosis can be obtained in approximately three-quarters of evaluable patients across a generalizable cohort based on prospective 12-month follow-up in a pragmatic setting with a low procedural complication rate.
电磁导航支气管镜(ENB)是一种微创技术,可引导内镜工具到达肺部病变部位。ENB 主要在小型单中心研究中进行了评估;因此,其在可推广环境中的诊断效果尚不清楚。
NAVIGATE 是一项前瞻性、多中心队列研究,使用 SuperDimension 导航系统(美敦力公司,明尼苏达州明尼阿波利斯市)评估 ENB。在这项美国队列分析中,2015 年 4 月至 2016 年 8 月,在 29 个学术和社区站点共纳入 1215 例连续患者。
中位病变大小为 20.0 毫米。91%的病例(60%的病变可见)使用透视,57%的病例使用径向支气管内超声。ENB 规划时间中位数为 5 分钟;ENB 特定手术时间为 25 分钟。在 1157 例接受 ENB 引导活检的患者中,94%(1157 例中有 1092 例)完成了导航并获取了组织。99%的患者在 1 个月时完成了随访,80%的患者在 12 个月时完成了随访。12 个月的诊断率为 73%。ENB 辅助组织样本的病理结果显示恶性肿瘤占 44%(1092 例中有 484 例)。恶性肿瘤的敏感性、特异性、阳性预测值和阴性预测值分别为 69%、100%、100%和 56%。ENB 相关的不良事件通用术语标准等级 2 或更高的气胸(需要住院或放置胸管)发生率为 2.9%。ENB 相关的不良事件通用术语标准等级 2 或更高的支气管肺出血和等级 4 或更高的呼吸衰竭发生率分别为 1.5%和 0.7%。
NAVIGATE 表明,在基于前瞻性 12 个月随访的实用环境中,大约四分之三的可评估患者可以通过 ENB 辅助诊断,并发症发生率低。